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Abstract
Background A prognostic model based on the results of molecular analysis of sentinel lymph nodes (SLN) is needed to 
replace the information that staging the entire axilla provided. The aim of the study is to conduct an external validation of a 
previously developed model for the prediction of 5-year DFS in a group of breast cancer patients that had undergone SLN 
biopsy assessed by the One Step Nucleic Acid Amplification (OSNA) method.
Methods We collected retrospective data of 889 patients with breast cancer, who had not received systemic treatment before 
surgery, and who underwent SLN biopsy and evaluation of all SLN by OSNA. The discrimination ability of the model was 
assessed by the area under the ROC curve (AUC ROC), and its calibration by comparing 5-years DFS Kaplan–Meier esti-
mates in quartile groups of model predicted probabilities (MPP).
Results The AUC ROC ranged from 0.78 (at 2 years) to 0.73 (at 5 years) in the training set, and from 0.78 to 0.71, respec-
tively, in the validation set. The MPP allowed to distinguish four groups of patients with heterogeneous DFS (log-rank test 
p < 0.0001). In the highest risk group, the HR were 6.04 [95% CI 2.70, 13.48] in the training set and 4.79 [2.310, 9.93] in 
the validation set.
Conclusions The model for the prediction of 5-year DFS was successfully validated using the most stringent form of valida-
tion, in centers different from those involved in the development of the model. The external validation of the model confirms 
its utility for the prediction of 5-year DFS and the usefulness of the TTL value as a prognostic variable.
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Introduction
The sentinel lymph nodes (SLN) biopsy is consolidated 
as an effective procedure in the staging of solid tumors, 
especially in breast cancer [1–3]. For years, the exhaustive 
study of these lymph nodes through immunohistochemical 
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techniques, and particularly molecular methods [4] have 
resulted in an increased detection of minimal neoplastic 
involvement, which promoted research on its biologic and 
prognostic relevance in early diagnostics of breast cancer.
Several studies were conducted to determine the total 
tumor load (TTL) that would allow to avoid unnecessary 
axillary lymph node dissection (ALND), based on the pre-
diction of non-SLN affectation [5–8]. The ACOSOG Z0011 
study published in 2011 allowed to identify a group of breast 
cancer patients with positive SLN in which ALND could 
be omitted. This resulted in a considerable increase in the 
number of patients with affected SLN and no ALND [9–11].
Nodal involvement (pN) has been always considered one 
of the main prognostic predictors in early breast cancer [12]. 
However, due to the previously mentioned research works, 
its study is now restricted in many cases to the SLN  (pN(sn)), 
which might compromise its prognostic value. The PLUTTO 
study [13] was developed as the next logical step to collect 
evidence of the prognostic value of the TTL, defined as the 
sum of the copy number of CK19 mRNA detected in every 
SLN examined, expressed as a concentration (copies/μL).
This study concluded that the TTL allows to distinguish 
two groups of patients with different overall survival (OS) 
and disease-free survival (DFS), independently from other 
known prognostic factors, using a threshold of 25,000 cop-
ies/μL. From this evidence, prognostic models were devel-
oped for DFS, loco-regional DFS (LRDFS) and OS, based 
on TTL, the patient’s age, and a risk score derived from 
tumor characteristics.
The primary objective of the present study was to conduct 
an external validation of a previously developed model [13] 
for the prediction of 5-year DFS in patients with a diagnostic 
of breast cancer that had undergone SLN biopsy with TTL 
determination from one step nucleic amplification (OSNA) 
method. Secondary objectives were the validation of analo-
gous models for LRDFS and OS.
Patients and methods
We collected longitudinal data of a historic cohort of patients 
with breast cancer from eight different Spanish hospitals, 
who underwent SLN biopsy January 2008 to June 2014, 
and evaluation of all SLN by OSNA (without conventional 
histological evaluation). Exclusion criteria were carcinoma 
in situ, tumors with no expression of Cytokeratin 19 (CK19), 
cases with systemic primary treatments (chemotherapy or 
hormonotherapy), lack of information related to demograph-
ics, tumor, sentinel lymph node biopsy, breast cancer treat-
ment and follow-up in the clinical records, or when OSNA 
evaluation of SLN was not made with all, complete, excised 
SLN. The study was approved by the Ethical Review Board 
of each institution (reference IRB: 2017-4-3-HCUVA, 
Hospital Clínico Universitario Virgen de la Arrixaca, Mur-
cia, Spain). Given its retrospective nature, informed consent 
was not obtained, but patient privacy was protected by using 
a patient study number in the data collection and through a 
dissociated management of the data.
Data collected for each patient included clinicopatho-
logical characteristics as well as clinical follow-up. The 
risk score derived from tumor characteristics was computed 
by adding up the number of risk factors (size > 2 cm, lym-
phovascular invasion, ki67 > 20, HER2 positive, ER nega-
tive, PR negative, and tumor grading) [13]. Follow-up time 
was defined as the time from the SLN biopsy date to the 
last follow-up date or the event date (progression or death), 
whichever came first. Progression events were classified as 
local, regional or distant.
Statistical analysis
The sample size was determined using estimates from a 
previous study [13]. At least 25 events per variable have 
been advised as a minimum for the external validation of 
prognostic models [14]. Since the model to be validated has 
three variables (age, TTL and a risk score), 75 events were 
needed. Because this was exactly the number of events in the 
previous study (n = 950 patients), we planned to recruit 1000 
patients in the current study, allowing for a 5% of invalid 
cases.
Results are presented for both the cohort previously used 
to develop the prognostic models (training set), and the 
current study cohort (validation set). Data are described as 
counts (n) and percentages, mean (SD) or median (IQR), as 
appropriate.
According to recommendations for the validation of prog-
nostic Cox regression models [15], we proceeded as follows: 
(1) the Prognostic Index (PI), defined as the linear predictor 
of the previous Cox model equation fitted in the training set, 
was computed for the validation and training sets; model 
predicted probabilities (MPP) were also computed, without 
recalibration in the training set; (2) the PI and MPP distribu-
tions in both the training and validation sets were compared 
by graphical methods (density plots); (3) we estimated the 
regression coefficient for the PI in the test set, and we tested 
the hypothesis of unit slope by the likelihood ratio test; (4) 
a possible model misspecification or lack of fit was assessed 
by fitting a model including the PI with unit slope, as well 
as the variables used in developing the model (age, TTL 
and risk score), and testing the hypothesis that the coeffi-
cients of these variables are all null; (5) the discriminant 
ability of the model was assessed by computing the area 
under the ROC curve (AUC ROC), and its calibration by 
comparing the Kaplan–Meier curves for groups defined by 
the quartiles of the MPP, in the training and validation sets. 
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Hazard ratios (HR) for the three groups of higher risk were 
computed using a Cox model.
The log-rank test was used to compare survival curves. 
Statistical significance was declared in all analyses if 
p < 0.05. All analyses were conducted with the R language 
(version 3.5.0) [16].
Results
A total of 1089 patients from eight sites were considered 
for inclusion in the validation study. However, 200 patients 
were excluded due to violation of selection criteria (4), lack 
of data required for model validation (193) or both (3), so 
that the validation set included 889 patients.
Table 1 shows the main characteristics of patients in the 
training and validation sets. In the 889 validation patients, 
the median follow-up was 6.4 years (Q1 5.6; Q3 7.0), 84 had 
a DFS event, 67 had a LRDFS event, and 51 died. A total 
of 1367 lymph nodes were analyzed, 544 (61.2%) patients 
had zero positive nodes, 278 (31.3%) one positive node, 55 
(6.2%) had 2 positive nodes, 11 (1.2%) had 3 positives nodes 
and 1 (0.1%) had 4 metastatic SLNs. TTL values ranged 
from 0 to 27 × 106 CK19 mRNA copies/μL, with a median 
of 0 and IQR 3100. In 544 cases, TTL was 0. In the remain-
ing 345 patients who had non-null TTL values, the quartiles 
were 1400,  104, and  105. These figures were similar to those 
reported previously for the training set [13].
Validation of the DFS prognostic model
Figure 1 shows the distribution of the PI and the MPP of 
5-year DFS in the training and validation sets, that are 
almost identical.
When a Cox model was fitted to the validation data with 
the PI as single predictor, its slope did not significantly differ 
from 1 (χ2 = 0.031; d.f. = 1; p = 0.861) and was estimated as 
1.03 [95% CI 0.72, 1.33]. Moreover, the test of a possible 
model misspecification by forcing the PI slope to be one 
Table 1  Characteristics of patients in the training and validation sets
Data are summarized as n (%), mean (SD)*, or median [IQR]**, as 
appropriate
Training N = 950 Validation N = 889
Age (years)* 58.4 (13.1) 57.5 (12.0)
Sex (female) 944 (99.4%) 886 (99.7%)
Tumor type
 Lobular 83 (8.7%) 67 (7.6%)
 Ductal 797 (83.9%) 783 (88.2%)
 Other 70 (7.4%) 38 (4.3%)
Tumor grade
 1 275 (28.9%) 226 (25.4%)
 2 465 (48.9%) 424 (47.7%)
 3 210 (22.1%) 239 (26.9%)
Tumor size (mm)** 16.0 [11.0; 22.0] 17.0 [12.0; 23.0]
Lymphovascular invasion 185 (19.5%) 231 (26.0%)
Estrogen receptors 837 (88.1%) 796 (89.5%)
Progesterone receptors 767 (80.7%) 720 (81.0%)
HER2 overexpression 108 (11.4%) 118 (13.3%)
ki67 (%)** 15.0 [10.0; 25.0] 15.0 [8.00; 30.0]
Risk Score** 3.00 [2.00; 4.00] 3.00 [2.00; 5.00]
Fig. 1  Distributions of the prognostic index (left) and model predicted probability of DFS at 5 years in the training and validation sets
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and adding the age, the risk score and the log(TTL + 1) as 
predictors, did not result in a significant improvement of the 
fit (χ2 = 3.07; d.f. = 3; p = 0.38). The discrimination ability 
of the model, as measured by the AUC of the ROC curve, 
showed a slight decline over time (as it is usually the case for 
models based on predictors assessed at start of follow-up), 
ranging from 0.78 at 2 years, to 0.73 at 5 years in the training 
set, and from 0.78 to 0.71 in the validation set.
Figure 2 displays the Kaplan–Meier curves for 5-year 
DFS in the four groups defined by quartiles of the MPP. 
The four curves were heterogeneous in both the training and 
the validation set (log-rank test p < 0.0001). The curves are 
very similar in groups 1 and 2, but progressively worse for 
groups 3 and 4.
Table  2 documents the Kaplan–Meier estimates of 
5-years DFS in the same four groups, and the hazard ratios 
(HR) for groups 2, 3 and 4 (group 1 as reference). The HR 
is not different from unit in group 2 but increases progres-
sively in groups 3 and 4. The difference between 5-year 
DFS estimates in the lowest and highest risk groups was 
0.975–0.831 = 0.144 (or 14.4%) in the training set, and 
0.976–0.866 = 0.11 (or 11.0%) in the validation set.
A nomogram to facilitate the utilization of the model is 
provided in Fig. 3.
Validation of the LRDFS and OS prognostic models
Prognostic models for LRDFS and OS that had been previ-
ously developed from the training data, were assessed using 
data from this validation study. In both cases, results were 
like those reported above for the DFS model, in that no evi-
dence of model misspecification was found. For the LRDFS 
model, the discrimination ability measured by the AUCROC 
ranged from 0.78 (at year 2) to 0.74 (year 5) in the training 
set, and from 0.76 to 0.70, respectively, in the validation set. 
For the OS model, values were 0.78 (year 2) and 0.73 (year 
5) in the training set, and 0.78 and 0.71, respectively, in the 
validation set.
Prognostic value of TTL > 25,000 (copies/μL)
According to the TTL value (CK19 mRNA copies/μL), the 
5-year DFS was lower in patients having TTL ≥ 25,000 than 
in those with TTL < 25,000 (p = 0.041).
Discussion
Our results document the external validity of a model previ-
ously developed to predict DFS from age, a risk score based 
on tumor characteristics, and TTL, in early breast cancer 
patients in whom SLN analysis was conducted by molecular 
methods. This model performed well when applied to a new 
sample of patients (validation set) recruited from centers dif-
ferent from those involved in its construction (training set). 
The discrimination ability of the model (AUC ROC) ranged 
from 0.78 (at 2 years) to 0.73 (at 5 years) in the training set, 
and from 0.78 to 0.71, respectively, in the validation set. 
Fig. 2  Kaplan–Meier curves of 
5-year DFS in the four groups 
defined by quartiles of the 
model predicted probabilities 
(MPP), and log-rank test, in the 
training and validation sets
Table 2  Kaplan–Meier 
estimates of 5-years DFS in 
groups defined by quartiles of 
MPP
Quartiles of MPP Training (n = 950) Validation (n = 889)
DFS (5 years) HR [95% CI] DFS (5 years) HR [95% CI]
1: MPP [0.962, 0.991] 0.975 – 0.976 –
2: MPP [0.940, 0.962) 0.957 1.42 [0.54, 3.73] 0.963 1.00 [0.396, 2.53]
3: MPP [0.902, 0.940) 0.923 2.84 [1.19, 6.79] 0.918 2.86 [1.350, 6.06]
4: MPP [0.453, 0.902) 0.831 6.04 [2.70, 13.48] 0.866 4.79 [2.310, 9.93]
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The quartiles of the MPP defined groups of patients with 
heterogeneous DFS curves (Fig. 2). The difference between 
the extreme groups in actual 5-years DFS probability was 
14.4% in the training set, and 11.0% in the validation set (see 
Table 2 and text).
Our study also confirmed significant different 5-years 
DFS according to the 25,000 copies/μL TTL threshold. 
However, this was only done as a way of documenting that 
TTL may contribute valuable information for 5-years DFS, 
but we do not suggest the use of any threshold [17] for pre-
diction or therapeutic decision making. In the model, TTL 
was introduced as a continuous variable, since categoriza-
tion is unnecessary, and has been shown to be inefficient in 
prognostic model development [18].
Extensive work has been done on the prediction of non-
SLN involvement from OSNA [5–8, 17, 19–22]. The prog-
nosis of breast cancer in terms of DFS and overall survival, 
has been studied in clinical trials [2, 10], and observational 
studies proposing tools for prediction [3, 13, 23, 24], most of 
them basing the prediction on ALND and/or tumor markers.
The Nottingham Prognostic Index (NPI) was developed 
long ago, using tumor size, grade, and lymph node staging 
from 387 patients recruited in a single center [23]. Lymph 
node involvement was based on biopsy of “a lower axillary 
node, an apical axillary node and a node from the internal 
mammary chain”. The NPI was subsequently applied (using 
conventional axillary lymph node staging) to large samples 
of patients from other populations with a variable degree of 
success [25, 26], but these exercises did not follow the stand-
ard methodology for the validation of prognostic models, 
and measures of model discrimination were not reported. 
Recently, a newer version of the NPI (NPLI Plus) has been 
proposed to predict development of distant disease [3].
A recent study proposed a nomogram for the predic-
tion of survival on the base of a modified lymph node ratio 
in breast cancer patients undergoing ALND [24]. In this 
study, patients that only received SLN biopsy were explic-
itly excluded (1328 out of 5736 patients that received sur-
gery, or 23%), and therefore their model and ours should 
be considered complementary. Their model showed a good 
discrimination capacity (c-index 0.789 in the validation set), 
though this was assessed by split-sample rather than external 
validation.
Validating a prognostic model means establishing that it 
works satisfactorily for patients other than those from whose 
data the model was derived. Neither internal validation (data 
splitting or cross-validation) nor temporal evaluation (subse-
quent patients within the same centers) addresses the wider 
issue of the generalizability of the model. As the goal of 
validation is to demonstrate satisfactory performance for 
patients from a different population from the original, it is 
clearly desirable to evaluate a model on new data collected 
from an appropriate patient population in different centers. 
For this reason, external validation is considered to be the 
most stringent form of validation [15, 27].
As mentioned in the 8th edition of the American Joint 
Committee on Cancer (AJCC) for breast cancer, the biology 
of the tumor should be considered for clinical and prognostic 
information [28]. Axillary staging (pN) is still an independ-
ent prognostic factor in early breast cancer patients; however, 
after the publication of the ACOSOG Z0011 trial and others, 
the therapeutic significance of ALND became questionable 
limiting the prognostic information of axillary involvement 
only to sentinel lymph node (pN(sn). Several models show 
a good prognostic value for positive SNL nevertheless, our 
prognostic model for early breast cancer based in an objec-
tive factor as is TTL and other outcomes may improve the 
management and follow-up of breast cancer patients using 
this variable. The validated model helps to identify patients 
with a lower 5-years DFS.
Fig. 3  Nomogram of the 
validated model to predict prob-
ability of DFS at 5 years
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Our study has several limitations. First, data were ret-
rospectively collected and, in general, retrospective data 
are less accurate and more prone to bias than prospec-
tive data. However, because the data were prospectively 
recorded, and their nature is not subjective, we think there 
is little risk of important inaccuracies. High inclusion rate 
of estrogen receptor positive patients, 88.1% in the train-
ing set and 89.5% in the validation set, as a result of uni-
formity subtype group could be considered a prognostic 
bias, nevertheless, patients included are representing a real 
sample of the population. Concerning a potential risk of 
bias, given our selection criteria we cannot think of any 
mechanism that could introduce a distortion in the predic-
tive ability of the model. Second, our model predicts DFS 
at 5 years, which is a minimum meaningful time to assess 
prognosis in early breast cancer. A longer time frame of 10 
or 15 years would be of great interest, but the molecular 
analysis of SLN is a relatively novel method [4], and its 
wide adoption in our environment dates less than 10 year 
ago [6, 7]. Definitely, another limitation is the need to get 
OSNA method which is not available in all centers; how-
ever, the use of molecular methods is recommended for a 
better prognostic precision, provided that the center can 
have it [28].Last, despite our selection criteria were not 
very restrictive, not all breast cancer patients satisfy them.
Conclusions
A prognostic model of 5-years DFS based on age, a tumor 
risk score, and TTL from SLN, was shown to be valid when 
applied to patients in centers different from those involved 
in its construction. The model was useful to identify patients 
that are at higher risk of disease progression, which may be 
interesting in a context of restrictive indication of ALND.
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